TABLE 2.
The clinical characteristics of CRO infections in 119 patients receiving polymyxin E sulfate based on different clinical responses.
| Variables | Total | Favorable clinical response (n = 64, 53.8%) | Unfavorable clinical response (n = 55, 46.2%) | P-value |
| Infection site (%) | ||||
| Pulmonary infections | 99(83.2%) | 56(87.5%) | 43(78.2%) | 0.175 |
| Bloodstream infections | 30(25.2%) | 16(25%) | 14(25.5%) | 0.955 |
| Abdominal infection | 16(13.4%) | 7(10.9%) | 9(16.4%) | 0.387 |
| Urinary tract infections | 12(10.1%) | 9(14.1%) | 3(5.5%) | 0.120 |
| Intracranial infections | 6(5.0%) | 5(7.8%) | 1(1.8%) | 0.285 |
| ≥2 Infection Sites | 45(37.8%) | 25(39.1%) | 20(36.4%) | 0.762 |
| CRO (%) | ||||
| CRAB | 86(72.3%) | 51(79.7%) | 38(61.9%) | 0.124 |
| CRKP | 40(33.6%) | 23(35.9%) | 18(32.7%) | 0.850 |
| CRPA | 11(9.2%) | 4(6.3%) | 7(12.7%) | 0.224 |
| Other CREs | 5(4.2%) | 1(1.6%) | 4(7.3%) | 0.276 |
| SM | 24(20.2%) | 13(20.3%) | 11(20.0%) | 0.966 |
| ≥ 2 Types of CRO | 48(40.3%) | 24(37.5%) | 24(43.6%) | 0.496 |
| Baseline condition | ||||
| Serum albumin, g/L, mean ± SD | 32.83 ± 5.09 | 33.55 ± 4.30 | 31.99 ± 5.81 | 0.095 |
| eGFR, mL/min/1.73 m2, mean ± SD | 79.91 ± 36.68 | 84.24 ± 37.36 | 74.86 ± 35.55 | 0.165 |
| SCr, μmol/L, median (range) | 78.00(55.00–129.00) | 75(52.75–110.75) | 79(57–147) | 0.309 |
| WBC, 109/L, median (range) | 10.05(7.25–14.58) | 10.88(8.29–16.02) | 9.1(5.84–13.16) | 0.050 |
| Neutrophil count, 109/L, median (range) | 8.48(0–13.63) | 8.94(6.93–14.37) | 7.77(4.54–11.86) | 0.059 |
| PCT, μg/L, median (range) | 1.62(0.41–5.59) | 1.32(0.40–5.62) | 1.85(0.43–5.59) | 0.583 |
| Post-treatment indicators | ||||
| p-Neutrophil count, 109/L, median (range) | 8.43(4.78–12.75) | 8.62(5.58–12.55) | 7.8(4.23–13.27) | 0.304 |
| p-PCT, μg/L, median (range) | 1.16(0.30–3.83) | 0.46(0.18–1.65) | 2.76(0.98–9.97) | 0.000 |
SD, standard deviation; CRO, carbapenem-resistant organisms; CRAB, carbapenem-resistant Acinetobacter baumannii; CRKP, carbapenem-resistant Klebsiella pneumoniae; CRPA, carbapenem-resistant Pseudomonas aeruginosa; CRE, carbapenem-resistant Enterobacteriaceae; SM, Stenotrophomonas maltophilia; eGFR, estimated glomerular filtration rate; SCr, serum creatinine; WBC, white blood cell count; PCT, procalcitonin; p-, post-treatment.